Canada & Steve N. Slilaty
3 shared events · Importance 3 · Last updated Jun 25, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
Canada: Canada is the market where Sunshine Biopharma's generic Rivaroxaban tablets received approval, contributing to the Canadian pharmaceutical market.
Steve N. Slilaty: Steve N. Slilaty, CEO of Sunshine Biopharma, expressed satisfaction with the approval of Rivaroxaban, highlighting its importance for the company's generics market position.
Jun 01, 2026 · 6 articles
Regulatory
Canada: Canada is the market where Sunshine Biopharma received regulatory approval for its generic Anastrozole tablets, representing a significant market for the company's expansion.
Steve N. Slilaty: Steve N. Slilaty, CEO of Sunshine Biopharma, expressed satisfaction with the approval of Anastrozole, highlighting its importance for the company's generics portfolio and commitment to affordable medicines.
Jun 25, 2026 · 6 articles
Business
Steve N. Slilaty: Dr. Steve N. Slilaty, CEO of Sunshine Biopharma, authorized the board to consider a reverse stock split.
May 18, 2026 · 7 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how Canada and Steve N. Slilaty interact across events, view sentiment trends, and discover connected entities.
Open Dashboard